Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + drug + 0.26  Related to the article below (Last Update: 8/4/2008)

Nailing drug use during pregnancy
separationsNOW.com (subscription), UK -
0.12-0.20 ng/mg (6), 0.10-0.15 ng/mg (4) and 0.12-0.26 ng/mg (5). The samples containing morphine and methadone contained no other drugs. ...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results
MarketWatch -
"We continue to build on our chemistry-based drug discovery platform for designing TLR-targeted compounds. We have selected IMO-3100 as a lead TLR ...IDRA - PINK:RCRS
Select another date
Seeking Alpha, NY -
10:56 AM Schering-Plough (SGP +0.4%) sends shares of rival Vertex (VRTX -11.6%) tumbling after a positive interim report for its new hepatitis drug. ...ATH:ASCO - C - LTS
Richard Aster Jr Buys Cooper Industries Ltd., Covidien Ltd ...
GuruFocus.com, TX -
Charles River is the global leader inproviding the animal research models required in research and development for new drugs devices and therapies and has ...CEPH - AEO - SCUR
Raltegravir (Isentress) Effective Against Drug-Resistant HIV
MedPage Today, NJ - Jul 23, 2008
The results "usher in a new era for HIV therapy -- the expectation that combination regimens involving new agents can suppress even the most drug-resistant ...
Pharmacopeia Announces Second Quarter 2008 Financial Results
MarketWatch - Jul 31, 2008
The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established ...PCOP

Boston Globe
Business Highlights
Forbes, NY - Jul 23, 2008
The Dow rose 29.88, or 0.26 percent, to 11632.38 after rising nearly 100 points early in the session. On Tuesday, the blue chips gained 135 points. ...
Stocks advance following sharp drop in oil prices Providence Journal
all 530 news articles »
Stocks decline on worries about earnings, oil
The Associated Press - Jul 21, 2008
The market was also uneasy about earnings at drug makers Merck & Co. and Schering-Plough Corp. Both pharmaceutical companies fell after a new study showed ...
Tercica Reports Second Quarter 2008 Financial Results
MarketWatch - Jul 30, 2008
In a meeting on July 15, 2008 with the Food and Drug Administration (FDA), Tercica discussed the development program for Somatuline(R) Depot in the ...TRCA - EPA:IPN
Celera Corporation Reports Fourth Quarter and Fiscal 2008 Results
MarketWatch - Jul 23, 2008
Two new drugs, INTELENCE(TM) (etravirine) and PREZISTA(TM) (darunavir) from Tibotec Therapeutics, a division of Ortho Biotech Products, LP, are included in ...CRA - HEL:ATRAV
Source: Google News

[CITATION] Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies -
J Lazarou, BH Pomeranz, PN Corey - JAMA: The Journal of the American Medical Association, 1998 - JAMA
... fatal ADRIn was 0.19% (95% CI, 0.13%-0.26%) of hospital ... version (6K): [in this window]
[in a new window ... Incidence of adverse drug reactions (ADRs) in 39 studies ...

Ecstasy and new patterns of drug use: a normal population study -
W Pedersen, A Skrondal - Addiction, 1999 - Blackwell Synergy
... Ecstasy and new patterns of drug use 1701 ... Multinomial logistic regression of four
patterns of drug use on ... 1.3 (0.87? 1.99) 0.8 (0.56? 1.20) 0.4 (0.26? 0.62) ...

… , Cigarette, and Marijuana Use Patterns: An Analysis of Drug Use Progression of Young Adults in New … -
J Yu, WR Williford - Substance Use & Misuse, 1992 - informaworld.com
... 0.29* -0.23 -0.26' -0.23* -0.16 ... of involvement with drugs: A Guttman scalogram analysis
of adolescent drug use. ... Englewood Cliffs, New Jer- sey: Prentice-Hall. ...

New Drug Developments for Opportunistic Infections in Immunosuppressed Patients: Pneumocystis … -
SF Queener - Journal of Medicinal Chemistry, 1995 - pubs.acs.org
... New Drug Developments for Opportunistic Infections in Immunosuppressed Patients:
Pneumocystis ... 0.003 0.054 ND 0.26 66 ... PABA, used as an index of drug effect, was ...

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression … -
J Geddes, N Freemantle, P Harrison, P Bebbington - BMJ: British Medical Journal, 2000 - pubmedcentral.nih.gov
... random effects standardised weighted mean difference was -0.09 (-0.07 to -0.26),
whereas in ... to advocate the first line use of a new drug without clear ...

Influence of first-pass effect on availability of drugs on oral administration -
M Gibaldi, RN Boyes, S Feldman - J Pharm Sci, 1971 - doi.wiley.com
... The plasma flow model sug- gests an even greater effect, yielding a mean f-value
of 0.26. ... a new drug and then applying a calculation similar to Eq. ...

Strategic Pricing of New Pharmaceuticals -
ZJ Lu, WS Comanor - Review of Economics and Statistics, 1998 - MIT Press
... e (2) The variables are defined as follows: LRELP Natural logarithm of the
ratio of the intro- ductory price of a new drug to the aver- ...

Adverse Reactions to New Anticonvulsant Drugs. -
ICK Wong, SD Lhatoo - Drug Safety, 2000 - drugsafety.adisonline.com
... discontinuation of lamotrigine are 0.2 and 0.26%, respectively ... should not unduly
deter the prescription of this drug. ... one of the most popular new anticonvulsants ...

Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal … -
K Sakai, XM Gao, T Hashimoto, CA Tamminga - Synapse, 2001 - doi.wiley.com
... Haloperidol, but neither new drug, decreased SP mRNA in the lateral ... by treatment
with any of the three drugs (Table II ... 10 301.9 20.5 10 F (3,39) 0.26, P 0.8525 ...

Levosimendan. -
DP Figgitt, PS Gillies, KL Goa - Drugs, 2001 - drugs.adisonline.com
... no evidence of any increase in the development of new supraventricular or ... volume;
the distribution half-life (t ?? ) of unchanged drug was 0.26 and 0.1 ...

Source: Google Scholar
 
 

A New Way Of Classifying Addictive Drugs

Article Date: 16 Nov 2006 - 12:00pm (PST)
Although addictive drugs have diverse molecular targets in the brain, they share the common initial effect of increasing the concentration of a substance called dopamine. In an article in PLoS Medicine, researchers Christian Luscher (University of Geneva) and Mark A. Ungless (Imperial College London) review recent research that has advanced our understanding of the molecular mechanisms underlying this increase of dopamine. Based on this research, they propose a new classification for addictive drugs. The authors say that this new classification "may help in directing research towards more effective treatment of addiction."

###

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (http://www.plosmedicine.org/) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Article continues below and (thank you)
 
Citation: Luscher C, Ungless MA (2006) The mechanistic classification of addictive drugs. PLoS Med 3(11): e437.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030437

About PLoS Medicine<.i>

PLoS Medicine<.i> is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org/

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visithttp://www.plos.org/

Contact: Andrew Hyde
Public Library of Science
 

Adult Pig Stem Cells Show Promise In Repairing Animals' Heart Attack Damage


Johns Hopkins scientists have successfully grown large numbers of stem cells taken from adult pigs' healthy heart tissue and used the cells to repair some of the tissue damage done to those organs by lab-induced heart attacks. Pigs' hearts closely resemble those in humans, making them a useful model in such research.

Following up on previous studies, Hopkins cardiologists used a thin tube to extract samples of heart tissue no bigger than a grain of rice within hours of the animals' heart attacks, then grew large numbers of cardiac stem cells in the lab from tissue obtained through biopsy, and within a month implanted the cells into the pigs' hearts. With help from a blue-dye tracking system, the scientists have shown that within two months the cells had developed into mature heart cells and vessel-forming endothelial cells.

"This is a relatively simple method of stem cell extraction that can be used in any community-based clinic, and if further studies show the same kind of organ repair that we see in pigs, it could be performed on an outpatient basis," says Eduardo Marban, M.D., Ph.D., senior study author and professor and chief of cardiology at The Johns Hopkins University School of Medicine and its Heart Institute. "Starting with just a small amount of tissue, we demonstrated that it was possible, very soon after a heart attack, to use the healthy parts of the heart to regenerate some of the damaged parts."

Marban cautions that no overall improvements in heart function have yet been shown in these studies, which were not designed to establish such changes and used relatively low numbers of infused cells (10 million or less). "But we have proof of principle, and we are planning to use larger numbers of cells implanted in different sites of the heart to test whether we can restore function as well," he says. "If the answer is yes, we could see the first phase of studies in people in late 2007."

The latest Hopkins findings were presented Nov. 13 at the American Heart Association's annual Scientific Sessions in Chicago. They are believed to be the first results in animal studies to show that so-called cardiac stem cell therapy can be successfully applied with minimally invasive methods to circumstances closely resembling those in humans. Scientists say the results build on earlier studies with cardiac stem cells in mice and humans that demonstrated success in regenerating infarcted heart muscle and restoring heart cell function post-infarct.

For the study, cardiac stem cells were extracted by tissue biopsy from eight pigs whose main arterial blood supply was tightened for more than two hours, duplicating the effects and damage caused by heart attack.

Using techniques developed in Marban's lab, researchers extracted about a million cardiac stem cells from undamaged heart tissue, growing them without the use of potentially dangerous chemical stimulators.

After three weeks, the stem cells turned into spherical balls of cells that mimicked the electrical properties of heart muscle cells. The so-called cardiospheres yielded on average more than 14 million cells.

Within a month after the initial heart attack, a catheter tube was inserted into an artery in the pig leg for infusing the cardiospheres. Previous research had shown that they would on their own migrate to the damaged zones of the heart. Marbᮧs team was able to confirm this because they had labeled the stem cells with a gene that codes for an enzyme producing a blue dye, which could be seen under a microscope.

Months later, when researchers examined the hearts to see if any damaged tissue had been repaired, they found blue spots indicating where the stem cells had taken root. Closer examination of results revealed that stem cells had matured and grown in the border zones of the damaged area, where researchers suspect both dead and living tissue mingle and some blood supply remains.

"The goal is to repair heart muscle weakened not only by heart attack but by heart failure, perhaps averting the need for heart transplants," says Peter Johnston, M.D., study author and a Reynolds Foundation postdoctoral cardiology research fellow at Hopkins' Heart Institute. "By using a patient's own adult stem cells rather than a donor's, there would be no risk of triggering an immune response that could cause rejection."

###

The studies were supported by the Donald W. Reynolds Foundation. Coauthors were Tetsuo Sasano, M.D.; Kevin Mills; Amr Youssef, M.B.B.Ch., M.Sc.; Mark Pittenger, Ph.D.; and Richard Lange, M.D. Marban is also the Michel Mirowski, M.D., Professor of Medicine at Hopkins and director of its Donald W. Reynolds Cardiovascular Clinical Research Center and the Institute of Molecular Cardiobiology. Johnston's work on this study was recently recognized at Hopkins, on Oct. 26, with one of three Stanley L. Blumenthal Cardiology Research Awards.

(Presentation title: Isolation, expansion and cardiac delivery of cardiac-derived stem cells in porcine model of myocardial infarction.)

Contact: David March
Johns Hopkins Medical Institutions
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page